Bioxytran, Inc. (BIXT)
Bioxytran, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Needham, MA, US. The stock last traded at $0.02, up 15.89% on the session, giving a market capitalisation of $2.5M. On trailing twelve-month figures it carries a trailing P/E of -0.94, a net margin of 0.0%. Its beta of 1.97 implies it has historically moved more than the broad market.
Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in Newton, Massachusetts.
Bioxytran, Inc. is most often compared with the following Healthcare names: